Clinical Trials

Phase 2 Active not recruiting

Neurofibromatosis 1, Neurofibroma, Plexiform

NCT02407405 2026-03-05

MEK 1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas

36 enrolled

Neurofibromatosis 1, Neurofibroma, Plexiform

NCT05005845 2026-02-17

NFX-179 Topical Gel Treatment for Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF)

199 enrolled 15 charts

Neurofibromatosis 1

NCT05253131 2026-02-11

Trial of Selumetinib and Bromodomain Inhibitor With Durvalumab for Sarcomas

Phase 2 Active not recruiting

41 enrolled

CNSSarcoma

Neurofibromatosis 1, Sarcoma, Neurofibrosarcoma

NCT02964884 2025-06-24

Interventions for Reading Disabilities in NF1

120 enrolled

Dyslexia, Learning Disabilities, Neurofibromatosis 1

NCT02728388 2025-05-08

Photodynamic Therapy for Benign Dermal Neurofibromas- Phase II

Phase 2 Recruiting

30 enrolled

Neurofibroma, Neurofibromatosis 1

NCT03231306 2025-05-02

NF108-BINI

45 enrolled 8 charts

Neurofibroma, Neurofibromatosis 1, Peripheral Nervous System Neoplasms, Neurofibromatoses, Neurofibroma, Plexiform

NCT06763315 2025-01-08

LS-NF1PNs

50 enrolled

Neurofibromatosis 1, Neurofibroma, Plexiform

NCT01553149 2025-01-07

Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma

75 enrolled 17 charts

Phase 2 Active not recruiting

Astrocytoma, Neurofibromatosis 1, Optic Nerve Glioma

NCT04481048 2024-10-09

DoDNAC

58 enrolled

Neurofibromatosis 1

NCT06620354 2024-10-01

Clinical Study on the Treatment of Type I Neurofibromatosis With Smeitinib Hydrosulfate Capsule

33 enrolled

Neurofibromatosis 1

NCT06621082 2024-10-01

The Clinical Study of the Treatment of Patients With Type I Neurofibromatosis With Smetinib Hydrosulfate Capsule

19 enrolled

Neurofibromatosis 1

NCT03741101 2024-04-11

plexifpc

Phase 2 Unknown

15 enrolled

Neurofibromatosis 1, Neurofibroma, Plexiform

NCT02332902 2023-12-20

DCLNF1

24 enrolled 4 charts

Neurofibroma, Neurofibromatosis 1

NCT02839720 2023-12-06

Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Cutaneous Neurofibroma

11 enrolled 11 charts

Neurofibromatosis 1, Optic Nerve Glioma

NCT03504501 2023-11-30

SynCoRAS

16 enrolled

Cognition Disorders, Neurofibromatosis 1, Noonan Syndrome

NCT00846430 2023-08-30

Medical Treatment of "High-Risk" Neurofibromas

9 enrolled 9 charts

Neurofibroma, Neurofibromatosis 1

NCT05825365 2023-08-14

PROTECT

Phase 2 Withdrawn

Neurofibromatosis 1, Neurofibroma, Plexiform

NCT05331105 2023-05-31

HL-085 in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas

Phase 2 Recruiting

70 enrolled

Neurofibromatosis 1, Neurofibroma, Plexiform

NCT04435665 2022-08-09

NFX-179 Topical Gel Treatment in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF)

48 enrolled 14 charts

Neurofibromatosis 1

NCT01968590 2022-05-25

VitDBoneNF1

26 enrolled

Neurofibromatosis 1

NCT01125046 2021-01-22

Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas

50 enrolled 13 charts

Brain Neoplasms, Ependymoma, Meningioma, Neurofibromatosis 1, Neuroma, Acoustic, Neurofibromatosis 2

NCT03109301 2019-04-05

Mitogen Activated Protein Kinase Kinase (MEK1/2) Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in People With Neurofibromatosis Type 1 (NF1) Mutated Gastrointestinal Stromal Tumors (GIST)

Phase 2 Withdrawn

Neoplasms, Nerve Tissue, Neurofibromatosis 1, Peripheral Nervous System Diseases, Neurofibroma, Plexiform, Heredodegenerative Disorders, Nervous System

NCT02096471 2019-01-10

MEK Inhibitor

19 enrolled 14 charts

Neurofibroma, Neurofibromatosis 1

NCT00304083 2018-09-18

Combination Chemotherapy in Treating Patients With Stage III or Stage IV Malignant Peripheral Nerve Sheath Tumors

48 enrolled 10 charts

CNSSarcoma

Neurofibromatosis 1, Sarcoma, Neurofibrosarcoma

NCT00030264 2018-08-08

Combination Chemotherapy in Treating Patients With Neurofibromatosis and Progressive Plexiform Neurofibromas

23 enrolled 9 charts

CNSOther neoplasm

Neurofibromatosis 1, Precancerous Conditions, Neurofibroma, Plexiform

NCT00076102 2018-04-23

Pirfenidone in Children and Young Adults With Neurofibromatosis Type I and Progressive Plexiform Neurofibromas

36 enrolled 13 charts

Neurofibromatosis 1, Nerve Sheath Neoplasms, Neurofibroma, Plexiform

NCT00021541 2018-04-17

R115777 to Treat Children With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas

62 enrolled 13 charts

Neurofibroma, Neurofibromatosis 1, Neurofibromatoses, Neurofibroma, Plexiform

NCT00853580 2018-03-12

STARS

146 enrolled 29 charts

Neurofibromatosis 1

NCT00634270 2017-11-17

Protocol 102

58 enrolled 19 charts

Neurofibromatosis 1

NCT03090971 2017-10-26

Use of Topical Liquid Diclofenac Following Laser Microporation of Cutaneous Neurofibromas in Patients With NF1

7 enrolled

Neurofibromatosis 1

NCT00326872 2017-08-18

AZD2171 in Treating Patients With Neurofibromatosis Type 1 and Plexiform Neurofibroma and/or Neurofibroma Near the Spine

26 enrolled 8 charts

Neurofibromatosis 1, Neurofibroma, Plexiform

NCT01365468 2016-05-12

Efficacy and Safety of RAD001 in Treating Plexiform Neurofibromas (PN) Associated With Neurofibromatosis (NF1)

9 enrolled 8 charts

Neurofibromatosis 1, Neurofibroma, Plexiform

NCT00589784 2016-01-25

Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma

50 enrolled 6 charts

Brain Neoplasms, Meningioma, Neurofibromatosis 1, Neurofibromatosis 2, Central Nervous System Neoplasms, Neurofibromatoses, Hemangioblastoma

NCT01412892 2014-11-14

NFitor

30 enrolled